| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
24,270,000 |
| Market
Cap: |
517.44(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.03 - $40.81 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fulgent Genetics is a holding company. Through its subsidiaries, Co. is a technology company providing COVID-19 testing services, molecular diagnostic testing services and genetic testing designed to provide physicians and patients with clinically actionable diagnostic information to improve the quality of patient care. Co. has developed a proprietary technology platform allowing Co. to provide a test menu. Combining next generation sequencing with its technology platform, Co. performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet customer needs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
29,577 |
54,115 |
78,957 |
| Total Sell Value |
$0 |
$791,434 |
$1,639,451 |
$2,902,369 |
| Total People Sold |
0 |
3 |
3 |
4 |
| Total Sell Transactions |
0 |
6 |
19 |
36 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Xie Jian |
President and COO |
• – – |
2022-05-01 |
4 |
D |
$54.88 |
$40,501 |
D/D |
(738) |
336,874 |
|
- |
|
| Gao Hanlin |
Chief Scientific Officer |
• – – |
2022-04-30 |
4 |
D |
$54.88 |
$15,531 |
D/D |
(283) |
856,062 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2022-03-03 |
4 |
S |
$56.31 |
$25,564 |
D/D |
(454) |
155,574 |
|
-4% |
|
| Bolger John C |
Director |
– • – |
2022-03-01 |
4 |
S |
$61.27 |
$115,056 |
D/D |
(1,875) |
2,000 |
|
7% |
|
| Bolger John C |
Director |
– • – |
2022-03-01 |
4 |
OE |
$3.93 |
$15,972 |
D/D |
1,875 |
2,625 |
|
- |
|
| Xie Jian |
Chief Operating Officer |
• – – |
2022-03-01 |
4 |
S |
$63.30 |
$39,370 |
D/D |
(622) |
337,612 |
|
7% |
|
| Gao Hanlin |
Chief Scientific Officer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
41,000 |
856,345 |
|
- |
|
| Xie Jian |
Chief Operating Officer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
41,000 |
338,234 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
41,000 |
156,028 |
|
- |
|
| Xie Jian |
Chief Operating Officer |
• – – |
2022-02-15 |
4 |
D |
$66.49 |
$62,235 |
D/D |
(936) |
297,234 |
|
- |
|
| Gao Hanlin |
Chief Scientific Officer |
• – – |
2022-02-15 |
4 |
D |
$66.49 |
$20,146 |
D/D |
(303) |
815,345 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2022-02-15 |
4 |
D |
$66.49 |
$73,737 |
D/D |
(1,109) |
115,028 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2022-02-03 |
4 |
D |
$63.15 |
$50,899 |
D/D |
(806) |
116,137 |
|
- |
|
| Xie Jian |
Chief Operating Officer |
• – – |
2022-02-03 |
4 |
D |
$63.15 |
$254,431 |
D/D |
(4,029) |
298,170 |
|
- |
|
| Xie Jian |
Chief Operating Officer |
• – – |
2022-02-01 |
4 |
D |
$65.34 |
$32,931 |
D/D |
(504) |
302,199 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2022-01-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,000 |
116,943 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2021-12-02 |
4 |
S |
$83.16 |
$51,558 |
D/D |
(620) |
120,943 |
|
31% |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2021-11-18 |
4 |
S |
$97.46 |
$48,731 |
D/D |
(500) |
131,826 |
|
33% |
|
| Xie Jian |
Chief Operating Officer |
• – – |
2021-11-16 |
4 |
S |
$95.50 |
$115,940 |
D/D |
(1,214) |
303,339 |
|
33% |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2021-11-16 |
4 |
S |
$95.50 |
$159,393 |
D/D |
(1,669) |
132,326 |
|
33% |
|
| Gao Hanlin |
Chief Scientific Officer |
• – – |
2021-11-16 |
4 |
S |
$95.50 |
$29,701 |
D/D |
(311) |
815,648 |
|
33% |
|
| Xie Jian |
Chief Operating Officer |
• – – |
2021-11-03 |
4 |
D |
$88.12 |
$520,260 |
D/D |
(5,904) |
304,553 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2021-11-03 |
4 |
D |
$88.12 |
$104,070 |
D/D |
(1,181) |
133,995 |
|
- |
|
| Xie Jian |
Chief Operating Officer |
• – – |
2021-11-01 |
4 |
D |
$86.79 |
$64,051 |
D/D |
(738) |
310,457 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2021-09-02 |
4 |
S |
$94.29 |
$57,235 |
D/D |
(607) |
135,176 |
|
14% |
|
281 Records found
|
|
Page 6 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.17 (0.79%) 
